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Researchers have observed that response of tumor cells to treatment varies depending on whether the cells are grown inmonolayer,
as in vitro spheroids or in vivo. This study uses data from the literature on monolayer treatment of SK-N-SH neuroblastoma cells
with 15-deoxy-𝑃𝐺𝐽2 and couples it with data on growth rates for untreated SK-N-SH neuroblastoma cells grown as multicellular
spheroids. A linear model is constructed for untreated and treated monolayer data sets, which is tuned to growth, death, and
cell cycle data for the monolayer case for both control and treatment with 15-deoxy-𝑃𝐺𝐽2. The monolayer model is extended to a
five-dimensional nonlinear model of in vitro tumor spheroid growth and treatment that includes compartments of the cell cycle
(𝐺1, 𝑆, 𝐺2/𝑀) as well as quiescent (𝑄) and necrotic (𝑁) cells. Monolayer treatment data for 15-deoxy-𝑃𝐺𝐽2 is used to derive a
prediction of spheroid response under similar treatments. For short periods of treatment, spheroid response is less pronounced than
monolayer response. The simulations suggest that the difference in response to treatment of monolayer versus spheroid cultures
observed in laboratory studies is a natural consequence of tumor spheroid physiology rather than any special resistance to treatment.
1. Introduction
Cancer therapies are tested thoroughly on monolayer layers
to identify not only their effectiveness but also the specific
manner in which they impede cell division or induce apop-
tosis. It is understood that the effectiveness of treatment in
monolayer does not predict equivalent effectiveness in vivo.
However, tumor spheroids cultured in vitro are considered
somewhat similar to small nodal tumors in a preangiogenic
state [1]. Both cases have actively proliferating cells near a
nutrient source, quiescent cells farther from that source, and
necrotic cells at a farther distance from nutrient. Spheroids
grown in vitro are probably a better predictor of therapeutic
response of small nodal tumors than in vitro monolayer
layers.
As part of a study onmetronomic therapy of breast cancer,
Klement et al. [2] published three examples of increasing
concentrations of treatments on resistant cell lines, compar-
ing the effect on monolayer versus spheroid cultures. Their
experiments included three treatments, adriamycin, vinblas-
tine, and cisplatinum, on resistant cell lines MD22, MVB9,
and CDDP-S4. Their results showed a clear discrepancy in
response to treatment, with monolayer cultures showing a
substantial growth reduction in response to increased con-
centrations of each of the three treatments, while spheroid
cultures showed a far less marked decrease in growth in re-
sponse to the same concentrations. As an example of this
phenomenon, when sufficient vinblastine was applied to
monolayers of MVB9 to reduce proliferating cells at 24
hours to around 20% of the untreated monolayer, the same
concentration applied to the spheroid culture reduced the
spheroid to approximately 80% of the untreated spheroid
after 72 hours.This pattern held for the other cell lines as well
[2]. As the experiments terminated after only a few days, it is
not known whether either culture would be completely killed
by continued treatment.
The results of this paper raise a few questions which
may be approached through simulations. The first is whether
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it is likely that the results in Klement et al. [2] would be
replicated with other cell lines and other treatments. In
particular, that study used cell lines which were known to
be resistant to the treatments applied. It would be useful
to know whether to expect a similar result with tumor cell
lines that are not particularly resistant to a given treatment.
One should also ask to what extent this differential response
to treatment is a natural consequence of tumor spheroid
physiology. Unlike monolayers, spheroids exhibit a tripartite
anatomy of proliferating, quiescent, and necrotic cells [3].
Unlike monolayers, spheroids spontaneously cease growth
[4]. Perhaps the physiological processes inherent in spheroid
development provide a natural protection against certain
therapies. A model of spheroid growth and response to
therapy would allow in silica experiments that answer these
questions and would be a useful predictor for therapeutic
response of preangiogenesis in vivo tumor nodes.
The spontaneous cessation of tumor spheroid growth
was conjectured to be due to the inability of nutrients to
penetrate to the core of the spheroid, which subsequently
undergoes necrosis [4]. The limits of diffusion, however, do
not rule out the existence of large spheroids with a small outer
layer of proliferating cells, thin enough to receive nutrients.
Numerical experiments confirm that diffusion of nutrients
alone is insufficient to explain cessation of growth [5, 6].
Further in vitro experiments show that the necrotic core
produces tumor necrosis factors that inhibit proliferation
[7]. A specific factor, known as TNF-𝛼, has been shown to
induce apoptosis in actively proliferating cells [8, 9]. Several
tumor spheroidmodels, incorporating tumor necrosis factors
as a source of apoptosis of proliferating cells, produce in
silica spheroids with qualitatively correct development [10].
In these models overall spheroid growth ceases without
resorting to an artificial restraint. That is, growth ceases
because of the interference of tumor necrosis factor in these
models, and when that factor is removed growth does not
cease. Furthermore, thesemodels exhibit a range of behaviors
consistent with qualitative observations of in vitro spheroids
[4, 7].
To make sense of how model simulations can reflect
therapies, it is necessary to tune general models with good
qualitative behavior to the specifics of a particular cell line
and therapy.This paper considers treatment of SK-N-SHneu-
roblastoma cells with 15-deoxy-𝑃𝐺𝐽2. Kim et al. [11] conduct
a series of experiments of increasing concentrations of 15-
deoxy-𝑃𝐺𝐽2 on monolayer layers. They concluded that the
treatment both inhibits proliferation at the 𝐺2/𝑀 stage and
induces apoptosis at that stage. Data for both the untreated
and treated cell lines are given in that paper. Data for
untreated spheroids of the same cell line is given in Carlsson
et al. [1].
The data published in these two papers [1, 11] and the
general models for spheroid growth [10] are the basis for
developing amore complex spheroidmodel that incorporates
cell cycle dynamics. It preserves the qualitative behaviors
observed in spheroids [4, 7], while tuning to cell cycle dy-
namicsmeasured in [11] and spheroid growth dynamicsmea-
sured in [1]. Therapeutic parameters derived from mono-
layer experiments of Kim et al. are then applied to the
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Figure 1: A cell cycle model (compartments 𝐺1, 𝑆, and 𝐺2) is
extended to include spheroid dynamics, including quiescent cells
(𝑄) and the necrotic core (𝑁). Rates are indicated near arrows.
Quantities 𝐵, 𝐶, and 𝐹 are dependent on the state of the system. If
parameters are chosen so that 𝐹 = 0 and 𝐵 = 1, the resulting model
simulates monolayer growth.
spheroid growth model, and the results are compared with
the response of monolayers.
2. Analysis
The nonlinear dynamic model developed here includes five
compartments, 𝐺1, 𝑆, 𝐺2, 𝑄, and 𝑁. The first three of these,𝐺1, 𝑆, and 𝐺2, correspond to the stages of the cell cycle.
The cell cycle leads to equations that include four quantities
of the same name, 𝐺1, 𝑆, 𝐺2, and 𝑀. However the data in
the literature tends to combine measurements for 𝐺2 and𝑀, so in the model the compartments for 𝐺2 and 𝑀 are
combined into just one compartment,𝐺2. To reflect spheroid
anatomy, quiescent cells, 𝑄, are an additional compartment.
The dead necrotic core,𝑁, must be included because it is part
of the measurement of total spheroid size and because it has
an effect on proliferation through TNF-𝛼. The compartment
model is illustrated in Figure 1.
2.1. A Tuned Linear Model of Monolayer Growth. Monolayer
layers exhibit exponential growth, at least in the short run,
and the cell cycle for such cultures is modeled by a system of
ordinary differential equations given below.
The rate of change of 𝐺1 is given by transition (upon
doubling) from 𝐺2 minus transition into 𝑆:𝐺󸀠1 = 2𝑐2𝐺2 − 𝑐1𝐺1. (1)
The rate of change of 𝑆 is given by transition from 𝐺1 to 𝑆
minus transition into 𝐺2:𝑆󸀠 = 𝑐1𝐺1 − 𝑐𝑆𝑆. (2)
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The rate of change of 𝐺2 is given by transition from 𝑆 to𝐺2minus transition (upon doubling) into𝐺1 andminus some
death rate: 𝐺󸀠2 = 𝑐𝑆𝑆 − 𝑐2𝐺2 − 𝑑𝑎𝐺2. (3)
Writing the system as 𝑋󸀠 = 𝐴𝑋, we expect solutions of
the form
𝑋 = 𝑒𝜆𝑡(𝑔
∗
1𝑠∗𝑔∗2). (4)
Here 𝑋∗ satisfies 𝐴𝑋∗ = 𝜆𝑋∗, where 𝜆 = ln(2)/𝐷 and 𝐷
is the doubling time for the culture.The numbers (𝑔∗1 , 𝑠∗, 𝑔∗2 )
are the proportions of cells in each stage in the limit. As
the cultures used in the monolayer experiments are not
synchronized, it is also the proportion of cells in each stage at
the start of the run, more or less. Plate experiments generally
indicate a death rate for the control (untreated) culture,
allowing us to deduce 𝑑𝑎, or natural death due to apoptosis.
The equation 𝐴𝑋∗ = 𝜆𝑋∗ leads to three linear equations
that can be solved in terms of experimentally derived quanti-
ties, (𝑔∗1 , 𝑠∗, 𝑔∗2 , 𝑑𝑎, 𝜆), to give
𝑐2 = (𝜆 + 𝑑𝑎𝑔∗2 )𝑔∗2 ,
𝑐1 = (2𝑐2𝑔∗2 − 𝜆𝑔∗1 )𝑔∗1 ,
𝑐𝑆 = (𝑐1𝑔∗1 − 𝜆𝑠∗)𝑠∗ .
(5)
These equations were tuned to monolayer data in Kim et al.
[11].
Using the Routh-Hurwitz Criterion, we determined that
the monolayer dies out when 𝑐2 < 𝑑𝑎 and persists, otherwise.
This can be easily shown by noting that the characteristic
equation for the linear system is 𝜆3 + 𝑎2𝜆2 + 𝑎1𝜆 + 𝑎0 = 0,
where 𝑎0 = 𝑐1𝑐𝑆(𝑑𝑎 − 𝑐2), 𝑎1 = 𝑐1𝑐𝑆 + 𝑐1(𝑐2 + 𝑑𝑎) + 𝑐𝑆(𝑐2 + 𝑑𝑎),
and 𝑎2 = 𝑐1 + 𝑐𝑆 + (𝑐2 + 𝑑𝑎). The Routh-Hurwitz Criterion
states that all roots of the characteristic polynomial have
negative real part if and only if 𝑎0, 𝑎1, 𝑎2 > 0, and 𝑎2𝑎1 >𝑎0. The last three inequalities are immediately satisfied, and𝑎0 > 0 if and only if 𝑐2 < 𝑑𝑎. Consequently, 𝑐2/𝑑𝑎 = 1
represents a threshold between extinction and persistence of
the monolayer.
2.1.1. Tuning the Control (Untreated) Monolayer Model to
Data. Table 1 gives constants derived from data on mono-
layers of neuroblastoma cell line SK-N-SH. Doubling time
was not given in the main source paper [11] and was taken
as an average of several given in the literature [1, 12–16].
Equilibrium proportions, (𝑔∗1 , 𝑠∗, 𝑔∗2 ), of cells in each stage
of the cell cycle, were taken from the control run in Kim et
al. [11], with a slight adjustment so that they sum to 100%. As
reported in the same study,𝑑𝑎 was taken to be 0 for the control
run.
Table 1: Summary of cell cycle parameters for SK-N-SHmonolayer
culture (default parameters). Note that values for 𝑔∗1 , 𝑠∗, and 𝑔∗2 are
adjusted slightly from Kim et al. [11] to sum to 100%.𝐷 is an average
over several studies (refer to Ross et al. (1981), Carlsson et al. (1983),
Biedler et al. (1978), Seeger et al. (1977), Barbier et al. (2001), and
Smets et al. (1991)).
Cell line SK-N-SH
Source Kim et al. (2003)
Observed 𝑔∗1 62.87%
Observed 𝑠∗ 26.93%
Observed 𝑔∗2 10.20%
Observed𝐷 n/a
Observed 𝑑𝑎 Taken as 0
Source 2 Multiple
Observed𝐷 𝐷 = 1.77 days
Calculated 𝜆 0.40
Calculated 𝑐1 0.85
Calculated 𝑐𝑆 1.59
Calculated 𝑐2 3.85
2.1.2. Modeling Treatments on Monolayers. The experiments
described in Kim et al. [11] include data on treatments of
15-deoxy-𝑃𝐺𝐽2 at various concentrations, applied to the SK-
N-SH cell line. The authors conclude that 15-deoxy-𝑃𝐺𝐽2
acts both to arrest cells in the 𝐺2/𝑀 stage and to induce
apoptosis at that stage. These actions correspond to a change
in parameters 𝑐2 and 𝑑𝑎 in the cell cycle model. These
parameters were adjusted to give a local best match with data
for the experiments described by optimizing total percent
error in 𝐺1, 𝑆, and 𝐺2 and mortality over a reasonable range.
The resulting simulated data is in Table 2 along with the
reportedmeasured data for comparison purposes.Thematch
of simulation to data was better for the lower doses. Initial
conditions were set to a total volume of 1, with proportions
given by (𝐺1(0), 𝑆(0), 𝐺2(0)) = (𝑔∗1 , 𝑠∗, 𝑔∗2 ).
2.2. A Spheroid Model Incorporating the Cell Cycle. Wallace
and Guo [10] describe a class of models for spheroid growth
that consider proliferating, quiescent, and necrotic cells.
Various versions of these models were tested against a range
of qualitative observations [4, 7]. In order to preserve the
features of the cell cycle model given earlier, the proliferating
compartment in those earlier models is replaced with the
entire cell cycle, and simple transitions between proliferating
and other compartments are replaced with transitions that
depend on relative availability of nutrient or presence of TNF-𝛼. The goal was to revise and extend the models in [10] to
include cell cycle dynamics, while maintaining consistency
with qualitative observations of spheroid growth and simulta-
neously matching the data from [1]. A compartment diagram
is pictured in Figure 1.
The path to enter the quiescent state, 𝑄, is assumed to be
taken by some cells at the𝐺1 stage as an alternative to entering𝑆.The return fromquiescent to nonquiescent, which has been
observed [17], is assumed tomove the cell into the 𝑆 stage.The
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Table 2: Summary of treatment parameters for SK-N-SHmonolayer
culture. Initial conditions have total cells at 100, divided into
percents given by 𝑔∗1 , 𝑠∗, and 𝑔∗2 for the control (see Table 1).
Cell line SK-N-SH
Source Kim et al. (2003)
Treatment 15-Deoxy-𝑃𝐺𝐽2 for 24 hrs
Parameter(s) 𝑐2, 𝑑𝑎
Computed final total
control 147.83
Initial conditions for all
runs
𝑔1(0) = 62.87, 𝑠(0) = 26.93,𝑔2(0) = 10.30, 𝑇 = 100
Treatment intensity 2𝜇m
Fitted parameter 𝑐2,new = 0.47𝑐2, 𝑑𝑎,new = 0.60
Observed at 24 hrs
% 𝑔1, % 𝑠, % 𝑔2, % dead 57.9%, 25.5%, 16.6%, 8.04%
Computed: % 𝑔1, % 𝑠, % 𝑔2 56.33%, 27.28%, 16.39%
Computed total 119.34
Computed mortality 8%
Treatment intensity 4𝜇m
Fitted parameter 𝑐2,new = 0.29𝑐2, 𝑑𝑎,new = .59
Observed at 24 hrs
% 𝑔1, % 𝑠, % 𝑔2, % dead 51.9%, 26.4%, 21.7%, 10%
Computed: % 𝑔1, % 𝑠, % 𝑔2 51.34%, 26.78%, 21.88%
Computed total 109.90
Computed mortality 10.09%
Treatment intensity 8𝜇m
Fitted parameter 𝑐2,new = 0.19𝑐2, 𝑑𝑎,new = .87
Observed at 24 hrs
% 𝑔1, % 𝑠, % 𝑔2, % dead 48.2%, 23.1%, 28.7%, 17%
Computed: % 𝑔1, % 𝑠, % 𝑔2 47.73%, 27.54%, 24.72%
Computed total 97.37
Computed mortality 17.03%
Treatment intensity 12𝜇m
Fitted parameter 𝑐2,new = 0.001𝑐2, 𝑑𝑎,new = 1.3
Observed at 24 hrs.
% 𝑔1, % 𝑠, % 𝑔2, % dead 37.6%, 20%, 42.4%, 36%
Computed: % 𝑔1, % 𝑠, % 𝑔2 36.45%, 29.31%, 34.24%
Computed total 73.83
Computed mortality 26.25%
effect of necrosis on proliferating cells is assumed to occur
at the division stage via apoptosis [8, 9]. These assumptions,
pictured in Figure 1, yield the following equations. All units
are in volume, 106 𝜇m3.
The rate of change of 𝐺1 is given by transition (upon
doubling) from𝐺2, with fraction𝐹 undergoing apoptosis due
to TNF-𝛼 and fraction 1−𝐹 entering𝐺1, minus transition out
of 𝐺1 with fraction 𝐵 entering 𝑄 and 1 − 𝐵 entering 𝑆:
𝐺󸀠1 = 2𝑐2 (1 − 𝐹)𝐺2 − 𝑐1 (𝐵) 𝐺1 − 𝑐1 (1 − 𝐵)𝐺1. (6)
The rate of change of 𝑆 is given by transitions from𝐺1 and𝑄, minus transition out of 𝑆 into 𝐺2:𝑆󸀠 = 𝑐1 (𝐵) 𝐺1 + 𝐶𝑄 − 𝑐𝑆𝑆. (7)
The rate of change of 𝐺2 is given by transitions from 𝑆,
minus transition out of 𝐺2 with fraction 𝐹 undergoing apop-
tosis due to TNF-𝛼, fraction 1−𝐹 entering𝐺1, and natural or
therapy-induced death rate 𝑑𝑎:𝐺󸀠2 = 𝑐𝑆𝑆 − 𝑐2 (1 − 𝐹)𝐺2 − 𝑐2𝐹𝐺2 − 𝑑𝑎𝐺2. (8)
The rate of change of 𝑄 is given by transition from 𝐺1
with fraction 𝐵 entering 𝑄, minus transitions out of 𝑄 either
returning to 𝑆 or dying and entering𝑁:
𝑄󸀠 = 𝑐1 (1 − 𝐵)𝐺1 − 𝐶𝑄 − 𝑒𝑄. (9)
The rate of change of 𝑁 is given by death of cells in 𝑄,
minus dissolution of material in𝑁:
𝑁󸀠 = 𝑒𝑄 − 𝑚𝑁. (10)
When 𝐵 = 1 and 𝐶 = 𝐹 = 0, these equations are identical
for those of the cell cycle, producing a mass of proliferating
cells undergoing exponential growth. For the new case of a
spheroid, 𝐵 and 𝐹 are taken to be functions describing the
dependency of transition processes on availability of nutrient,
in the case of 𝐵, or amount of necrosis, in the case of 𝐹.
The parameter 𝐶 depends on the availability of nutrient
to 𝑄, which is blocked by the uptake of the nonquiescent
compartments𝐺1, 𝑆, and𝐺2. For convenience a new variable,𝑇, describes the sum of all compartments in the model, and
a second variable, 𝑃, describes the live, nonquiescent cells
(𝑃 = 𝐺1 + 𝑆 + 𝐺2). Extra apoptosis due to treatment, 𝑑𝑎𝐺2,
is assumed to occur at the transition from 𝐺2 to 𝐺1 as in the
linear model.
The passage of𝐺1 to 𝑆 in the linear model is controlled by
the constant 𝑐1, which in the extended model is taken to be
the maximum rate of transfer between these compartments,
as some of the𝐺1 cells are sent instead to the𝑄 compartment.
The function 𝐵 must range therefore between 0 and 1.
Nutrients, including oxygen, are assumed to enter the cell
at a spherical boundary, so for a fixed amount of 𝐺1 the
function 𝐵 should increase to 1 or decline to 0 with surface
area proportional to 𝑇2/3. As the proportion of proliferating
cells increases relative to surface area, 𝐵 should decline to
zero, allocating more cells to the 𝑄 compartment. A class of
functions that behaves this way is given by
𝐵 = 𝑇2/3𝑠1 + 𝐺1 + 𝑇2/3 . (11)
The return from the quiescent state to the proliferating
state would occur for some fraction of cells when nutrients
cease to be blocked by the nonquiescent cells, 𝑃. Little data
is available on this process, although it has been observed
to happen when hypoxic conditions are relieved [17]. Here
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Table 3: Summary of spheroid growth data estimated fromCarlsson
et al. [1].
Type, cell line (Day, reporteddiameter in mm),𝑊 Thickness of viablecell rim at end of trial(day, 𝑉)
Neuroblastoma,
SK-N-SH
(2, 0.19), (7, 0.21), (11,
0.27), (15, 0.32), (19,
0.35), (25, 0.39), (31,
0.41)
(31, 50–150 𝜇m)
the process is modeled by a function of 𝑃 and surface area
proportional to 𝑇2/3, which is assumed to have a maximum
rate of 𝑐𝑞 when surface area is large compared to 𝑃 and which
approaches a minimum rate of 0 when surface area is small
compared to 𝑃.
A class of functions that behaves this way is given by
𝐶 = 𝑐𝑞 𝑇2/3𝑠𝑞 + 𝑃 + 𝑇2/3 . (12)
Both functions 𝐵 and 𝐶 have the property that they
go to zero as overall spheroid size goes to zero. This is
not a biologically reasonable behavior, as no cells would be
expected to become quiescent at very small spheroid size.
A more biologically reasonable function would be given by𝑠1 = 0, but then numerical difficulties could occur at small
values.The given formulation of the functions 𝐵 and𝐶works
well for spheroid sizes greater than 1. As themodel is designed
for spheroids on the order of 106 𝜇m3 the effect near zero is
easily avoided for small 𝑠1 and 𝑠𝑞. Both 𝑠1 and 𝑠𝑞 have been
set to 0.0001.
Finally, the fraction of cells at the 𝐺2 stage that reproduce
or die is determined by the presence of TNF-𝛼 [8, 9] which
is assumed to be present in proportion to the amount of
necrotic tissue, 𝑁. The maximum rate at which apoptosis
could occur is assumed to be less than the intrinsic rate 𝑐2 at
which that stage of the cell cycle proceeds. A class of functions
describing this choice is given by
𝐹 = 𝑁𝑠𝑛 + 𝑁. (13)
These equations were tuned to spheroid culture data in
Carlsson et al. [1], while fixing the constants derived from
monolayer data.
2.2.1. Tuning the Control (Untreated) Spheroid Culture Model
to Data. Cell cycle parameters 𝑐1, 𝑐𝑠, 𝑐2, and 𝑑𝑎 were kept
the same as for control monolayer data described in Table 1.
Spheroid diameters over time are reported as a figure in
Carlsson et al. [1]. Table 3 gives estimated values read from
that table. Spheroid volumes were computed from diameter
data in Table 3, reported in Table 4. Although this paper does
not give cell cycle data, it does report a monolayer doubling
time of 40–50 hours, consistent with the average used in
Table 1. On the last day of the experiment, the thickness of the
viable cell rim was recorded via light microscopy. More than
Table 4: Summary of default parameters for spheroid model.
Spheroid volumes and viable cell volume estimated from Table 3.
Unspecified parameters from Table 1. 𝑃 = 𝐺1 + 𝑆 + 𝐺2. Initial
conditions: 𝑁 = 0, 𝑄 = 0, 𝐺1 = 2.26, 𝑆 = .969, and 𝐺2 = .359,
at time 𝑡 = 2.
Cell line SK-N-SH
(Time, computed volume) (2, 3.59 ∗ 106 𝜇m3)
(Time, computed volume) (7, 4.85 ∗ 106 𝜇m3)
(Time, computed volume) (11, 10.0 ∗ 106 𝜇m3)
(Time, computed volume) (15, 17.0 ∗ 106 𝜇m3)
(Time, computed volume) (19, 22.0 ∗ 106 𝜇m3)
(Time, computed volume) (25, 31.0 ∗ 106)
(Time, computed volume) (31, 36.0 ∗ 106)
(Time, computed volume of
necrosis (𝑁)) (31, (15.6–4.85) ∗106 𝜇m3)
(Time, computed volume of
live cells (𝑇 − 𝑁)) (31, (20.5–31.25) ∗106 𝜇m3)
Chosen 𝑠1 0.0001
Fitted 𝑐𝑞 0.1212
Chosen 𝑠𝑞 0.0001
Fitted 𝑠𝑛 61.0520
Fitted 𝑒 0.4898
Fitted𝑚 .0528𝑃 + 𝑄(𝑡 = end) 12.65𝑃 + 𝑄 + 𝑁(𝑡 = end) 35.94𝑁(𝑡 = end) 23.29𝑆(𝑡 = end) 2.23𝑇∗ 36.76𝑁∗ 25.59
twenty spheroids were tested, and clearly there was a lot of
variation in this number. Table 4 gives the volumes of live and
necrotic compartments computed from the data in Table 3.
The two most difficult parameters to identify from data
are 𝑠1 and 𝑠𝑞, which describe the functional response of
proliferating and quiescent cells to the presence of nutrient.
Although it plays an important role in spheroid physiology,
the quiescent compartment,𝑄, is difficult tomeasure without
explicit cell cycle data. It is notmeasured in the study towhich
this model is tuned. A simpler assumption would be that
the functional response is given by a direct proportion, with𝑠1 = 𝑠𝑞 = 0. Instead, an arbitrary choice of 𝑠1 = 𝑠𝑞 = 0.0001
gives a functional response that is almost a direct proportion,
while avoiding any numerical difficulties that could arise if
the denominator were to get small. This choice was made
after some experimentation and still gave a decentmatchwith
data.
Four parameters remain to be identified. Of these, two
(𝑚, 𝑠𝑛) control the relative size of the live versus dead com-
partments. Summing (6) through (10) at equilibrium yields
the relation
𝐺∗2 = 𝑚𝑐−12 𝑁∗ (𝑠𝑛 + 𝑁∗)𝑠𝑛 − 𝑁∗ . (14)
6 Computational and Mathematical Methods in Medicine
Numerical exploration indicates that the two parameters
that appear in this equation, 𝑚 and 𝑠𝑛, do indeed have the
biggest effect on the final values of𝑁 and 𝑇 − 𝑁. In order to
have a positive quantity of proliferating cells at equilibrium, 𝑠𝑛
must be greater than𝑁∗. Experimentally, the highest volume
of the spheroid is about 36(∗106 𝜇m3). Starting with a value
of approximately twice that, 𝑚 and 𝑠𝑛 were adjusted to give,
in order of priority, a final volume at 𝑡 = 31 (29 days) close to
36, with live and dead cell volumes in the reported ranges.
Two parameters remain, 𝑐𝑞 and 𝑒, describing transition
rates from 𝑄 to 𝑆 and from 𝑄 to 𝑁, respectively. As 𝑄 is
not measured directly, the impact of these parameters is
strictly visible in the total growth pattern. More cells in
the proliferating compartments will create faster growth. To
fit these, a MATLAB best fit program was used on the
growth data for total volume over time. Fitted parameters are
reported in Table 4.
In addition to matching data, overall long-term behavior
of the model was compared to qualitative observations and
was found to behave well. Initial conditions for all data
matching and treatment simulations were set by the volume
of the first data point in [1], assuming that all cells are in the
proliferating compartment (𝑄(0) = 0,𝑁(0) = 0), distributed
in the ratio given by (𝐺1(0), 𝑆(0), 𝐺2(0)) = (𝑔∗1 , 𝑠∗, 𝑔∗2 ).
2.2.2. Simulation of Treatments on Spheroids. With all param-
eters specified for the model of an untreated SK-N-SH
spheroid, it only remains to alter those parameters corre-
sponding to treatment with 15-deoxy-𝑃𝐺𝐽2. The parameters
involved, 𝑐2 and 𝑑𝑎, were set according to their derived values
in Table 2. The linear monolayer model was run for 24 hours
whereas the spheroid model was run for 72 hours in order
to see a bigger effect. The study by Klement et al. [2] showed
a noticeable difference in response between monolayer and
spheroid cultures. This response was measured by a methyl-
[3H]-thymidine incorporation assay, which labels cells in the𝑆 phase of the cell cycle [18]. This measurement is some-
times considered a proxy for the proliferating compartment.
Figure 6 shows relative effect sizes for the 15-deoxy-𝑃𝐺𝐽2
concentrations studied in Kim et al. [11].
2.2.3. Bifurcation Analysis of Spheroid Model. To determine
the impact of treatment intensity on spheroid volume and
persistence of the spheroid, we performed a bifurcation
analysis of the spheroid model. In particular, we calculated
numerically (using the MATLAB function “lsqnonlin”) the
volume of proliferating, quiescent, and necrotic cells at
equilibrium as a function of 𝑑𝑎, the rate of 𝐺2 apoptosis, for
choices of 𝑐2 corresponding to the five treatment intensities,𝑐2 and 𝑐2,new = .001𝑐2, 0.19𝑐2, 0.29𝑐2, 0.47𝑐2.
3. Results
3.1. Monolayer Models. Rapidly growing tumor monolayers
exhibit characteristic doubling times, death rates, and cell
cycle proportions that are enough to determine a linear
model completely, leading to simple algebraic expressions
for all parameters. Data for treated monolayers are another
matter. In the example studied here, two parameters, 𝑐2 and
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Figure 2: Simulated monolayer treatment of SK-N-SH neuroblas-
toma cells with 15-deoxy-𝑃𝐺𝐽2 at varying concentrations. Curves are
labeled by the value of 𝑐2, with keys as follows: (control, 𝑐2 = 3.85,𝑑𝑎 = 0), (2𝜇M, 𝑐2,new = 0.47𝑐2, 𝑑𝑎,new = 0.60), (4𝜇M, 𝑐2,new = 0.29𝑐2,𝑑𝑎,new = .59), (8𝜇M, 𝑐2,new = 0.19𝑐2, 𝑑𝑎,new = .87), and (12𝜇M,𝑐2,new = 0.001𝑐2, 𝑑𝑎,new = 1.3).
𝑑𝑎, corresponding to researchers’ best understanding of the
action of 15-deoxy-𝑃𝐺𝐽2 on SK-N-SH cell lines were altered
in an effort tomatch treatment intensities of 2, 4, 8, and 12 𝜇M
concentrations, as in Figure 2. A good fit was obtained for the
low concentrations (2 and 4 𝜇M). At 8 𝜇m, the mortality rate
wasmatchedwell with some sacrifice of accuracy for cell cycle
proportions. At 12 𝜇M the cell cycle proportions produced by
the model did not match the data particularly well, as seen
in Figure 3. Mean squared error for 2, 4, and 8 𝜇M treatments
altogether is 3.5 percentage points.MSE for all treatments is 18
percentage points. This suggests that, at high concentrations,
other transitions are being affected besides the 𝐺2/𝑀 to 𝐺1
transition.
3.2. SpheroidModels. It is possible to extend the linear model
of the cell cycle in monolayer growth to a nonlinear model
of spheroid growth, as illustrated in Figure 1. Nonlinearity is
included in the transition rates between proliferating to qui-
escent cells and in the action of TNF-𝛼 in inducing apoptosis
at the𝐺2 stage. All transition rates in this model are bounded
by those determined by monolayer cell cycle data, with the
exception of the transition from quiescent to proliferating,
which was not measured. The model was tuned to a specific
cell line and treatment, giving growth curves as in Figure 4.
The model produces a spheroid that stops growing, has a
necrotic core, and whose proliferating compartment remains
alive; qualitative observations are reported in the literature
[4, 7].The tunedmodel fits the initial and final data quite well
but underestimated the intermediate measurements, as seen
in Figure 5.
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Figure 3: Model simulation of cell cycle analysis after 24 hours of treatment, versus measured values. Data is taken from [11]. The model
matches data well at low concentrations, with a poor match at 12𝜇M. Mean squared error for 2, 4, and 8𝜇M treatments all together is 3.5
percentage points. MSE for all treatments is 18 percentage points.
3.3. Treatment of Spheroids versus Monolayers. The purpose
of constructing these models was to simulate the different
response to treatment between monolayer and spheroid cul-
tures. Figure 6 illustrates this effect. Simulations of increased
concentrations of 15-deoxy-𝑃𝐺𝐽2 on SK-N-SH spheroids
produced noticeably less effect than on monolayers, even
when spheroids are treated for 72 hours instead of 24 hours. In
this particular example,monolayers are still growing in size at
2 and 4 micromolar concentrations, but at a greatly reduced
rate. At 8𝜇M, the colony size of a monolayer decreases.
By contrast, for spheroids, the total volume is finite and is
reduced by all treatments. However, the effect size is small.
Even though the total volume is reduced, the spheroid may
persist. Figure 7 shows a numerically computed bifurcation
analysis for the spheroid model, with vertical lines marking
critical values in themonolayermodel.The diagram indicates
that a lower intensity of treatment may suffice to drastically
reduce the size of a spheroid, as opposed to a monolayer.
However the effect of short-term treatment (2-3 days) may
produce a less marked response in the spheroid, as in
Figure 6. Figure 8 shows the effect of treatment sustained over
a long period, for parameters near the critical value for the
monolayer model. Although a therapy with these parameters
may not be biologically feasible, Figure 8 highlights the
difference in dynamics over a longer period.
4. Discussion
The behavior of the monolayer model under treatment
conditions is consistent with the conclusions in [11] that
treatment blocked the 𝐺2 to 𝐺1 transition (reducing 𝑐2) and
induced apoptosis (increasing 𝑑𝑎). As treatment intensity
increased, both of these fitted parameters moved in the
expected direction. At high intensity (12 𝜇M concentration)
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Figure 4: Model predictions for spheroid growth to 100 days. (a) Relative sizes of proliferating (𝑃), quiescent (𝑄), and necrotic (𝑁)
compartments. (b) Breakdown of the proliferating compartment into parts of the cell cycle on the right.
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Figure 5:The SK-N-SHneuroblastoma spheroidmodel with default
(control) parameters given in Tables 1 and 4. Total spheroid size is
graphed, along with the data from Carlsson et al. [1]. The proliferat-
ing compartment is also graphed. Note that day 0 corresponds to the
initial conditions given as day 2 in the data; similarly day 29 in the
image corresponds to day 31 in the data set taken from [1]. Note that
priority was given to getting a good fit for both 𝑇 and 𝑃 at the final
data point, with some sacrifice of accuracy at intermediate points.
Table 4 gives numerical data and model prediction for the last time
data.
the match of the model to cell cycle analysis data was not
good, indicating that perhaps other transitions in the cell
cycle were affected as well at this intensity. The monolayer
model is thus useful for pointing out a possible inconsistency
between the data and conclusions in [11] at higher intensities
of treatment.
Fitting a linear model to cell cycle information for a
monolayer can be done statistically. In (5) we give algebraic
expressions that compute the parameters for such a model.
Given the doubling time, death rate, and cell cycle analysis
for an unsynchronized culture, these equations produce the
remaining parameters necessary for the linear model.
Figure 6 was constructed in imitation of a similar figure
in Klement et al. [2], where treatment comparisons between
monolayer and spheroid cultures are given for three choices
of cell line (MD22, MVB9, and CDDP-S) and treatment
(adriamycin, vinblastine, and cisplatinum, resp.). The data
available for the example in this paper was coarser, but the
overall effect is the same. As the intensity of treatment goes
up, the spheroid shows a resilience that the monolayer does
not. This resilience is not due to evolved resistant strains,
which were neither present in the monolayer experiment nor
built into the simulations, but just to the overall anatomy
and physiology of the tumor spheroid, as represented by
the model. The simulations here suggest that one should
expect similar reduced response to treatment intensity from
nonresistant strains as well as resistant ones.
Our results give a spheroid model that not only has the
correct qualitative growth behavior [4] and not only matches
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Figure 6: Response of SK-N-SH neuroblastoma spheroid and monolayer models to increasing 15-deoxy-𝑃𝐺𝐽2 treatment concentration,
measured in micromolar concentrations as in [11]. Response of spheroid model (black) is given as percent of control after 3 days of growth.
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Figure 7: Bifurcation diagram for equilibrium of necrotic cells in
spheroidmodel. Each line represents the equilibrium volume of cells
at a different treatment intensity 𝑐2,new, as a function of 𝑑𝑎, in units
of 106 𝜇m3. Filled circles denote the equilibria using the fitted pair of
parameters (𝑐2,new, 𝑑𝑎,new) in Table 2 and Figure 2 (control, 𝑐2 = 3.85,𝑑𝑎 = 0), (2 𝜇M, 𝑐2,new = 0.47𝑐2, 𝑑𝑎,new = 0.60), (4 𝜇M, 𝑐2,new = 0.29𝑐2,𝑑𝑎,new = .59), (8 𝜇M, 𝑐2,new = 0.19𝑐2, 𝑑𝑎,new = .87), and (12𝜇M,𝑐2,new = 0.001𝑐2, 𝑑𝑎,new = 1.3). Vertical lines denote critical values for
the monolayer model (𝑑𝑎 = 𝑐2). At values of 𝑑𝑎 below these critical
values the monolayer grows exponentially. For values higher than
this it declines exponentially. Diagrams for the proliferating and
quiescent compartments (omitted here) are similar to this diagram.
Note that equilibrium values for all spheroid compartments drop to
near zero before the critical value for the monolayer model.
quantitative growth data for the control [1] but also gives
qualitatively correct response to therapy in comparison with
monolayer experiment [2, 11], an important new benchmark
for judging the qualitative accuracy of models. The results
presented here are an important step in constructing a com-
partment model that captures the fundamental properties
of in vivo tumor growth. Systems of ordinary differential
equations like these are quite simple compared to spatial
models but have the advantage that the full force of analytic
and control theoretic methods can be brought to bear on
them in future work.
The ability of the model to approximate spheroid growth
over time, while including cell cycle dynamics, shouldmake it
useful to the experimenter who wishes to predict the results
of specific therapeutic actions on preangiogenic tumors. Its
utility as a predictor fits the proposed workflow model in
McGuire et al. [19]. In particular, it can help a researcher
decide on a set of protocols for in vivo experiments. Figure 6
indicates that, for the example given in this paper, experi-
menters might have difficulty distinguishing the difference
in effect between 2, 4, and 8 𝜇M concentrations. It is easy to
see that a more extensive data set, even for just monolayer
treatments, could be coupled with this model to give more
insight into what intensities of treatment are likely to produce
a noticeable response.
Figure 8 shows that 𝑐2 has a big effect on long-term
dynamics of the spheroid model. Near the monolayer critical
value, reducing 𝑐2 has a bigger effect on final tumor size
than increasing 𝑑𝑎. This mathematical result highlights the
importance of blocking the 𝐺2 to 𝐺1 transition as a thera-
peutic goal. It suggests that a less toxic therapy that blocks
this transition but does not necessarily kill cells, applied
over a much longer duration, could be a useful therapeutic
tool. Models such as the one presented here should be part
of the conversation about metronomic therapies because
they identify possibilities for low level interventions which,
sustained long enough, may have therapeutic effect.
An accurate model for growth of in vitro spheroids
and their response to treatment is an important step in
constructing in silica representations of in vivo tumor growth.
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Figure 8: Long-term behavior of SK-N-SH neuroblastoma spheroid, under hypothetical continued treatment, at values of 𝑑𝑎 near the critical
threshold for the monolayer model. Dashed lines give the behavior for the monolayer model and solid lines give the behavior of the spheroid
model. For purposes of comparison, the initial conditions are given by the data set taken from [1], for both the spheroid and monolayer
models. Colors represent the five choices of 𝑐2 corresponding to the control and four treatment intensities. Note that a small change in 𝑑𝑎
creates a substantial response in the monolayer model, while the spheroid dynamics are not much different.
The example presented here shows the capacity of a model to
fit both qualitative and quantitative observations of spheroid
growth and treatment response, give insight into the mecha-
nisms of a particular therapy, and suggest strategies for future
therapies.
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